Skip to content

Influence of abutment transgingival height on peri-implant soft tissue and peri-implant marginal bone level: A prospective randomized clinical trial

Influence of abutment transgingival height on peri-implant soft tissue and peri-implant marginal bone level

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200058604
Enrollment
Unknown
Registered
2022-04-12
Start date
2022-03-29
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dentition defect

Interventions

Group A:Abutments of 1 mm transgingival height
Group B:Abutments of 2 mm transgingival height
Group C:Abutments of 3 mm transgingival height

Sponsors

Department of Oral Implantology, Hospital of Stomatology of Jilin University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: General inclusion criteria: 1. The patient voluntarily participates and signs the informed consent form; 2. Male or female aged >= 18 years; 3. American Society of Anesthesiologists (ASA) Grade I or Grade II; 4. Single crown or 1~3 unit combined crown planting repair is required; 5. Periodontal health or periodontitis has been treated and stabilized. Partial inclusion criteria: 1. At least 3 months after tooth extraction, the tooth extraction socket is completely healed; 2. Alveolar ridge width >= 7mm, distance from mandibular nerve >= 10mm, distance from maxillary sinus >= 8mm; 3. Mucosal thickness of implant repair site (initial mucosal thickness): 3~4mm; 4. The mandibular teeth are fixed prosthetic dentures or natural teeth, and the repair space is >= 6 mm.

Exclusion criteria

Exclusion criteria: 1. The patient is pregnant or lactating at any time during the study period; 2. The patient had uncontrollable endocrine, immune or metabolic changes during the study period; 3. Patients who need soft and hard tissue reconstruction technology; 4. Lack of initial implant stability or peak implant torque > 60 Ncm; 5. Poor oral hygiene and enthusiasm (plaque index > 20%), uncontrolled periodontal disease, or active infection or inflammation at the implant site; 6. Have any drug history that may affect the health of soft tissues (such as amlodipine, cyclosporine A, phenytoin sodium, etc.), drug history that may affect bone metabolism (such as bisphosphonate, etc.), or systemic diseases; 7. Full dose radiotherapy, local radiotherapy history of head or neck 8. Serious nocturnal molar, temporomandibular joint disorder and other related functional abnormalities or bad occlusion behavior or habits; 9. Smoking > 10 cigarettes/day; 10. Psychological or mental problems; 11. Alcoholism or drug abuse. 12. Participate in other studies if this protocol cannot be properly followed; 13. Other conditions that the researcher judged could not participate in the study.

Design outcomes

Primary

MeasureTime frame
peri-implant marginal bone level(MBL);

Secondary

MeasureTime frame
width of keratinized mucosa(KMW);bleeding on probing(BOP);probing pocket depth(PPD);facial mucosal level(FML);papilla height(PH);

Countries

China

Contacts

Public ContactLi Fu

Department of Oral Implantology, Hospital of Stomatology of Jilin University

fuli1127@jlu.edu.cn+86 13756027709

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026